Kissei Pharmaceutical Co., Ltd. (4547.T)
JPY 3795.0
(0.0%)
JPY 3795.0
(0.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 18.72 Billion JPY | 78.72% |
| 2022 | 17.8 Billion JPY | 11.95% |
| 2021 | 20.26 Billion JPY | -30.32% |
| 2020 | 10.64 Billion JPY | 1.99% |
| 2019 | 7.21 Billion JPY | -41.68% |
| 2018 | 9.75 Billion JPY | -26.34% |
| 2017 | 14.21 Billion JPY | 14.72% |
| 2016 | 12.51 Billion JPY | -13.42% |
| 2015 | 13.51 Billion JPY | 13.3% |
| 2014 | 12.7 Billion JPY | -21.79% |
| 2013 | 15.62 Billion JPY | 39.38% |
| 2012 | 10.42 Billion JPY | 1.94% |
| 2011 | 10.75 Billion JPY | 8.26% |
| 2010 | 9.19 Billion JPY | -4.96% |
| 2009 | 9.89 Billion JPY | -3.56% |
| 2008 | 7.17 Billion JPY | 25.37% |
| 2007 | 8.49 Billion JPY | 42.39% |
| 2006 | 6.57 Billion JPY | 1.09% |
| 2005 | 6.93 Billion JPY | -33.02% |
| 2004 | 11.19 Billion JPY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | 785 Million JPY | -57.83% |
| 2024 Q1 | 3.22 Billion JPY | 48.02% |
| 2023 Q2 | 459 Million JPY | -79.78% |
| 2023 Q1 | 2.27 Billion JPY | 256.12% |
| 2023 FY | - JPY | 78.72% |
| 2023 Q3 | 2.65 Billion JPY | 478.43% |
| 2023 Q4 | 990 Million JPY | -62.71% |
| 2022 Q1 | 816 Million JPY | 190.97% |
| 2022 FY | - JPY | 11.95% |
| 2022 Q2 | -503 Million JPY | -161.64% |
| 2022 Q3 | 1.66 Billion JPY | 430.02% |
| 2022 Q4 | -1.45 Billion JPY | -187.59% |
| 2021 Q2 | 256 Million JPY | -72.44% |
| 2021 Q3 | 116 Million JPY | -54.69% |
| 2021 FY | - JPY | -30.32% |
| 2021 Q4 | -897 Million JPY | -873.28% |
| 2021 Q1 | 929 Million JPY | 159.25% |
| 2020 Q1 | 2.11 Billion JPY | 452.92% |
| 2020 Q3 | 1.57 Billion JPY | 138.73% |
| 2020 FY | - JPY | 1.99% |
| 2020 Q4 | -1.56 Billion JPY | -199.37% |
| 2020 Q2 | 661 Million JPY | -68.73% |
| 2019 Q1 | 2.58 Billion JPY | 84.81% |
| 2019 Q4 | -599 Million JPY | -169.41% |
| 2019 Q3 | 863 Million JPY | 109.98% |
| 2019 FY | - JPY | -41.68% |
| 2019 Q2 | 411 Million JPY | -84.07% |
| 2018 FY | - JPY | -26.34% |
| 2018 Q3 | 1.09 Billion JPY | -18.61% |
| 2018 Q4 | 1.39 Billion JPY | 27.14% |
| 2018 Q1 | 3.52 Billion JPY | 111.46% |
| 2018 Q2 | 1.34 Billion JPY | -61.73% |
| 2017 FY | - JPY | 14.72% |
| 2017 Q4 | 1.66 Billion JPY | -64.92% |
| 2017 Q3 | 4.75 Billion JPY | 99.16% |
| 2017 Q2 | 2.38 Billion JPY | 6.28% |
| 2017 Q1 | 2.24 Billion JPY | 162.57% |
| 2016 FY | - JPY | -13.42% |
| 2016 Q1 | 3.63 Billion JPY | 499.01% |
| 2016 Q2 | 1.24 Billion JPY | -65.73% |
| 2016 Q3 | 3.69 Billion JPY | 196.15% |
| 2016 Q4 | 855 Million JPY | -76.85% |
| 2015 Q1 | 2.95 Billion JPY | 1060.06% |
| 2015 Q3 | 6.53 Billion JPY | 141.02% |
| 2015 Q2 | 2.71 Billion JPY | -8.32% |
| 2015 Q4 | -912 Million JPY | -113.96% |
| 2015 FY | - JPY | 13.3% |
| 2014 Q1 | 2.92 Billion JPY | 413.86% |
| 2014 FY | - JPY | -21.79% |
| 2014 Q4 | -308 Million JPY | -107.47% |
| 2014 Q3 | 4.12 Billion JPY | 33.45% |
| 2014 Q2 | 3.08 Billion JPY | 5.43% |
| 2013 Q4 | 570 Million JPY | -92.09% |
| 2013 FY | - JPY | 39.38% |
| 2013 Q1 | 3.54 Billion JPY | 449.46% |
| 2013 Q2 | 1.87 Billion JPY | -46.98% |
| 2013 Q3 | 7.2 Billion JPY | 283.29% |
| 2012 Q3 | 3.9 Billion JPY | 129.61% |
| 2012 FY | - JPY | 1.94% |
| 2012 Q2 | 1.7 Billion JPY | -28.88% |
| 2012 Q1 | 2.39 Billion JPY | 35.05% |
| 2012 Q4 | 645 Million JPY | -83.5% |
| 2011 Q1 | 2.68 Billion JPY | 54.85% |
| 2011 FY | - JPY | 8.26% |
| 2011 Q2 | 2.53 Billion JPY | -5.37% |
| 2011 Q3 | 3.83 Billion JPY | 51.14% |
| 2011 Q4 | 1.77 Billion JPY | -53.81% |
| 2010 Q4 | 1.73 Billion JPY | -53.24% |
| 2010 Q1 | 3.16 Billion JPY | 215.87% |
| 2010 FY | - JPY | -4.96% |
| 2010 Q2 | 1.39 Billion JPY | -55.83% |
| 2010 Q3 | 3.7 Billion JPY | 164.95% |
| 2009 Q2 | 3.03 Billion JPY | 10.32% |
| 2009 Q4 | 1 Billion JPY | -72.36% |
| 2009 Q3 | 3.62 Billion JPY | 19.4% |
| 2009 Q1 | 2.75 Billion JPY | -6.59% |
| 2009 FY | - JPY | -3.56% |
| 2008 Q2 | 625 Million JPY | 0.0% |
| 2008 FY | - JPY | 25.37% |
| 2008 Q3 | 3.21 Billion JPY | 414.24% |
| 2008 Q4 | 2.94 Billion JPY | -8.34% |
| 2007 FY | - JPY | 42.39% |
| 2006 FY | - JPY | 1.09% |
| 2005 FY | - JPY | -33.02% |
| 2004 FY | - JPY | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Pharma Foods International Co., Ltd. | 6.02 Billion JPY | -210.912% |
| Takeda Pharmaceutical Company Limited | 874.6 Billion JPY | 97.86% |
| Sumitomo Pharma Co., Ltd. | -281.07 Billion JPY | 106.66% |
| Shionogi & Co., Ltd. | 186.7 Billion JPY | 89.973% |
| Wakamoto Pharmaceutical Co.,Ltd. | 570.97 Million JPY | -3178.62% |
| Nippon Shinyaku Co., Ltd. | 36.29 Billion JPY | 48.416% |
| Kaken Pharmaceutical Co., Ltd. | 12.26 Billion JPY | -52.605% |
| Eisai Co., Ltd. | 103.1 Billion JPY | 81.844% |
| Morishita Jintan Co., Ltd. | 1.29 Billion JPY | -1347.796% |
| Hisamitsu Pharmaceutical Co., Inc. | 18.34 Billion JPY | -2.072% |
| Mochida Pharmaceutical Co., Ltd. | 8.97 Billion JPY | -108.626% |
| Fuso Pharmaceutical Industries,Ltd. | 3.67 Billion JPY | -410.082% |
| Nippon Chemiphar Co., Ltd. | 1.4 Billion JPY | -1234.284% |
| Tsumura & Co. | 30.77 Billion JPY | 39.165% |
| Torii Pharmaceutical Co., Ltd. | 5.27 Billion JPY | -255.151% |
| Towa Pharmaceutical Co., Ltd. | 35.53 Billion JPY | 47.321% |
| Fuji Pharma Co., Ltd. | 6.88 Billion JPY | -172.014% |
| Zeria Pharmaceutical Co., Ltd. | 17.52 Billion JPY | -6.839% |
| KYORIN Holdings, Inc. | 10.29 Billion JPY | -81.818% |
| Taiko Pharmaceutical Co.,Ltd. | -3.75 Billion JPY | 599.2% |
| Daito Pharmaceutical Co.,Ltd. | 7.55 Billion JPY | -147.849% |
| SymBio Pharmaceuticals Limited | -714 Million JPY | 2721.849% |
| MedRx Co., Ltd | -884.51 Million JPY | 2216.412% |
| Mizuho Medy Co.,Ltd. | 5.53 Billion JPY | -238.133% |
| Solasia Pharma K.K. | -635 Million JPY | 3048.031% |
| Modalis Therapeutics Corporation | -2.37 Billion JPY | 888.568% |
| ASKA Pharmaceutical Holdings Co.,Ltd. | 9.16 Billion JPY | -104.3% |
| Sawai Group Holdings Co., Ltd. | 36.87 Billion JPY | 49.231% |
| Cyfuse Biomedical K.K. | -538.28 Million JPY | 3577.686% |
| Toho Holdings Co., Ltd. | 25.84 Billion JPY | 27.568% |
| Koa Shoji Holdings Co.,Ltd. | 5.1 Billion JPY | -266.941% |